Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Catalyst Pharm Inc (NASDAQ: CPRX)


Last Updated: Apr-29-2016 20:10:44

CPRX News & Stock Updates

  • Biotech Boom: (Nasdaq: AMBI) and (Nasdaq: CPRX)

    Shares of Ambit Biosciences Corp. (Nasdaq: AMBI), surged more than 87% yesterday on news that the company will be purchased by Daiichi Sankyo Co. for nearly $315 million in cash. Meanwhile, shares of Catalyst Pharmaceuticals Partners Inc. (Nasdaq: CPRX) rose by more than 18% on positive news from its late-stage study on its Firdapse treatment. Catalyst said that it is planning […]

Premium Research

Catalyst Pharm Inc (NASDAQ: CPRX) Profile

Volume3,190,300
Open$0.65
Prior Close$0.63
Market Cap$0.06 B
PE Ratio
Beta0.99
CATALYST PHARMACEUTICAL PARTNERS INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
SymbolCompanyMarket cap
TKPYYTakeda Pharma$37.71 B
SHPGShire Plc Ads$36.26 B
ALPMYAstellas Pharma Inc$29.88 B
ZTSZoetis Inc. Class A Common Stoc$23.43 B
PCYCPharmacyclics Inc$19.73 B
VRXValeant Pharmaceuticals International$12.03 B
SLXPSalix Pharmaceuticals$11.1 B
GRFSGrifols S.A$10.84 B
JAZZJazz Pharma Plc$9.19 B
CBSTCubist Pharmaceuticals$7.79 B

CPRX Earnings

1st Quarter Earnings$ ()
2nd Quarter Earnings$ ()
3rd Quarter Earnings$ ()
4th Quarter Earnings$ ()
PE Ratio0
EPS Growth-26.67%
Recent Earnings$
Annual EPS$-0.19
Market Capitalization$0.06 B
Insider Shareholder %0.087%
Annual Revenue$0 B
Number of Shares Outstanding82,880 Shares
Institutional Shareholder %51.01%
Annual Net Income$0B
TTM Net Profit Margin$100.15
One Year Return-79.58%
Three Year Return-3.6%
Five Year Return-40.87%
Five Year Revenue Growth-100%
Five Year Earnings Growth13.64%
Five Year Dividend Growth0%
Last Quarter EPS$
Annual EPS$-0.19
Annual Dividend$0
Annual Dividend Yield0%
Change in EPS YTD-26.67%
PE Ratio
Recent Earnings$
Dividends per Share$
Stock Split Ratio
beta0.99

CPRX Key Stats

Last Price$0.68
Net Change$0.05 (7.94%)
Bid$0.5
Ask Price$0.79
Open Price$0.65
Previous Close Price$0.63
High Price$0.74
Low Price$0.63
Number of Trades3,500
Volume3,190,300
Fifty Two Week High$5.8 (2015-07-23)
Fifty Two Week Low$0.51 (2016-04-26)
Average Daily Volume1,025,094
Share Outstanding82,880 Shares
Total Dividend Payout$0/yr
Dividend Yield0%